ARCHIVES

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

This article is from The Cancer Letter archive.

Vol. 28 No. 8 | August 26, 2005

Download PDF Visit The Full Archive

Related Articles

House Subcommittee Rejects Doubling Budget For Cancer Research, Provides Increase To NIH

July 17, 2009

FDA Approves Inlyta Pill For Renal Cell Carcinoma

January 27, 2012

Senate Markup Of Labor-HSS-Education Money Bill Delayed Until After Congress August Recess

August 4, 1989

Panel Unenthused About New Toxicity Testing Program

December 15, 1978

DCE Board Approves Reissuing Epidemiology Small Grants PA

June 3, 1988

NCI Would Fund 3,164 research Project Grants, 897 Competition, Under FY92 While House Budget

February 15, 1991